Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Velia Chiara Di MaioSilvia BarbalisciaElisabetta TetiGianluca FiorentinoMartina MilanaStefania PaolucciTeresa PollicinoGiulia MorsicaMario StaraceBianca BruzzoneWilliam GennariValeria MicheliKatia Yu La RosaLuca ForoghiVincenza CalvarusoIlaria LenciEnnio PolilliSergio BabudieriAlessio AghemoGiovanni RaimondoLoredana SarmatiNicola CoppolaCaterina PasquazziFausto BaldantiGiustino ParrutiCarlo Federico PernoMario AngelicoAntonio CraxìMassimo AndreoniFrancesca Ceccherini-Silbersteinnull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
In this real-life GT3 cohort, the majority of failures harboured resistant variants carrying NS5A-RASs, the most frequent being Y93H. The presence of natural NS5A-RASs before treatment was associated with failure. Further analyses are needed to confirm this observation, particularly for the new current regimens.